



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

20 Apr 2015

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.

Please be advised that you **must contact the Research Grants Management Office (RGMO) at least 60 days before the submission date**, Mr Eugene Baugaard (eugeneb@sun.ac.za), or as soon as you commit to apply for an NIH grant and that the grant is submitted institutionally.

Important notices

- Notice of Potential Delays to NIH Issuing Awards in May 2015 ([NOT-OD-15-088](#))
- Racial and Ethnic Categories and Definitions for NIH Diversity Programs and for Other Reporting Purposes ([NOT-OD-15-089](#))
- Reporting Publications in the Research Performance Progress Report (RPPR) ([NOT-OD-15-090](#))
- Findings of Research Misconduct ([NOT-OD-15-092](#)) and ([NOT-OD-15-093](#))

1. Title: Limited Competition: International epidemiology Databases to Evaluate AIDS (IeDEA)

Letter of Intent due date: N/A **Hyperlink:** [\(RFA-AI-15-017\)](#) **Type:** UO1
Application Due Date: July 17, 2015, by 5:00 PM local time of applicant organization
Purpose: This Funding Opportunity Announcement (FOA) solicits applications to continue the International epidemiology Databases to Evaluate AIDS (IeDEA) Program. The IeDEA program is comprised of 7 regional data center awards, each of which brings together clinical and research data to answer questions concerning HIV/AIDS, the epidemiology of tuberculosis, hepatitis, cancer, as well as neurologic and mental health complications among adults and children affected by HIV/AIDS
Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. All applicants may request a project period of up to 5 years

2. Title: TaRGET II: Environmental Epigenomic Analysis in Tissue Surrogates

Letter of Intent due date: May 24, 2015 **Hyperlink:** [\(RFA-ES-15-001\)](#) **Type:** UO1
Application Due Date: June 24, 2015, by 5:00 PM local time of applicant organization.
Purpose: Environmental exposure induced perturbations of epigenomic marks are correlated with disease pathogenesis. Identifying changes in epigenomic marks (e.g., DNA methylation, histone modifications, chromatin accessibility) in affected tissues/cells is not always feasible in humans. The purpose of this Funding Opportunity Announcement (FOA) is to establish a consortium that will explore the conservation of perturbations of epigenomic marks across target tissues/cells and surrogate tissues/cells using mouse models of environmentally relevant diseases. Ultimately, these analyses will provide insights into the design and interpretation of human studies where target tissues are inaccessible.
Budget: Application budgets are limited to \$400,000 direct costs per year. The award project period is limited to 4 years.

3. Title: Pilot and Feasibility Clinical Trials in Diabetes, and Endocrine and Metabolic Diseases

Letter of Intent due date: N/A **Hyperlink:** [\(PA-15-176\)](#) **Type:** R21
Application Due Date: Standard dates apply (Jun 5, Oct 5, Feb 5) by 5:00 PM local time of applicant organization.
Standard AIDS dates apply (May 7, Sep 7, Jan 7) by 5:00 PM local time of applicant organization.
Purpose: This Funding Opportunity Announcement encourages the submission of pilot and feasibility trials conducted in humans that will lay the foundation for larger clinical trials related to the prevention and/or treatment of diabetes or selected endocrine and genetic metabolic diseases within the mission of NIDDK. The program will support short-term clinical trials in humans to acquire preliminary data and/or refine power calculations that would lead to a larger, more definitive study impacting clinical care or health outcomes.
Budget: Direct costs are limited to \$275,000 over a two-year period, with no more than \$200,000 in direct costs allowed in any single year.

4. Title: Post-market Surveillance of Generic Modified Release Products

Letter of Intent due date: May 8, 2015 **Hyperlink:** [\(RFA-FD-15-015\)](#) **Type:** UO1
Application Due Date: June 29, 2015, by 11:59 PM Eastern Time.
Purpose: The purpose of this study is to analyze use, substitution patterns, safety and effectiveness of generic modified release products, and compare them with their respective brand name drug products and other generic drugs with different formulation design characteristics. The outcome(s) of this study will help determine if there are differences in the patterns of use, substitution, and safety and effectiveness associated with the studied generic modified release products, and to provide further evidence regarding their substitutability for brand name drugs.
Budget: Application budgets need to reflect the actual needs of the proposed project and should not exceed \$500,000 in total costs (direct and indirect) for a two (2) year project period. It is the responsibility of the applicant to distribute up to \$500,000 in total costs between the two (2) budget years. The total costs (direct and indirect) for the entire two (2) year project period may not exceed \$500,000.

5. Title: Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials**Letter of Intent due date:** 30 days before the application due date **Hyperlink:** [\(PA-15-177\)](#) **Type:** R34**Application Due Date:** Standard dates apply (Jun 5, Oct 5, Feb 5) by 5:00 PM local time of applicant organization.
Standard AIDS dates apply (May 7, Sep 7, Jan 7) by 5:00 PM local time of applicant organization.

Purpose: This FOA for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and (b) pre-trial feasibility testing for prevention services and systems research. It is expected that research conducted via this R34 mechanism will consist of early stage efficacy, effectiveness or services research that will provide intervention pilot and/or feasibility data that is a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This R34 FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols; rather, any development work must be imbedded within a pilot/feasibility study. Of particular interest are prevention interventions targeting the healthcare system.

Budget: Applicants may request direct costs of up to \$450,000 for three years. Although variations from year to year are permissible, in no case may any year be more than \$225,000 in direct costs, and total direct costs for the entire project period may not exceed \$450,000. The maximum project period is 3 years.

6. Title: Research Partnerships for Going to Scale with Mental Health Interventions in Low-and Middle-Income Countries**Letter of Intent due date:** June 15, 2015 **Hyperlink:** [\(RFA-MH-16-350\)](#) **Type:** U19**Application Due Date:** July 15, 2015, by 5:00 PM local time of applicant organization.

Purpose: This Funding Opportunity Announcement solicits applications to address implementation questions facing World Bank designated low- and middle-income countries (LMICs) in their efforts to scale up sustainable, evidence-based mental health interventions and thereby eliminate the mental health care treatment gap for children, women, and men. The mental health treatment gap refers to the proportion of persons who need, but do not receive care. Each awarded project is to conduct implementation research and research capacity-building activities in LMICs in any one of the following geographical regions: East Asia and the Pacific; Europe and Central Asia; Latin America and the Caribbean; Middle East and North Africa; South Asia; Sub-Saharan Africa. As a group, awardees will constitute a network for mental health implementation research in LMICs with capabilities for answering research questions about going to scale with mental health interventions, sustaining high-quality mental health care in resource-limited settings, and fostering evidence-based mental health policy and program development on an ongoing basis. This program is not intended to support research that can be conducted primarily in and/or by United States or other high income country institutions.

Budget: Application budgets are limited to \$500,000 direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is five years.

7. Title: Undiagnosed Diseases Gene Function Research**Letter of Intent due date:** May 24, 2015 **Hyperlink:** [\(RFA-RM-15-004\)](#) **Type:** R21**Application Due Date:** June 24, 2015, by 5:00 PM local time of applicant organization.

Purpose: This Exploratory/Developmental Research Funding Opportunity intends to support gene function studies in collaboration with the Undiagnosed Diseases Network (UDN) building upon the NIH Intramural Research Program's Undiagnosed Diseases Program (NIH-UDP). Responsive applications will propose to investigate the underlying genetics, biochemistry and/or pathophysiology of newly diagnosed diseases in association with the respective gene variant(s) identified through the UDN. In recent years, gene function studies combined with genetic and genomic analyses and metabolic studies have greatly improved diagnoses of these very rare diseases and advanced scientific knowledge of the underlying pathogenesis. This initiative is funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact.

Budget: Application budgets should not exceed \$150,000 direct costs per year. The total award period is 2 years.

8. Title: Enhancing Regulatory Science for the Risk Based Assessment of Emerging Manufacturing Technologies**Letter of Intent due date:** 30 days before the application due date **Hyperlink:** [1](#) **zsa** **U01****Application Due Date:** June 30, 2015, by 11:59 PM Eastern Time. April 29, 2016, by 8:00 PM Eastern Time. April 28, 2017, by 8:00 PM Eastern Time. April 30, 2018, by 8:00 PM Eastern Time. April 30, 2019, by 8:00 PM Eastern Time. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date.

Purpose: The goal of this program is to support the advancement of regulatory science that can facilitate the implementation and the assessment of emerging manufacturing technology in the pharmaceutical sector. Emerging manufacturing technology can be viewed as a technology that has the potential to modernize the pharmaceutical manufacturing body of knowledge to support more robust, predictable, and/or cost-effective processes and with which the FDA has limited review or inspection experiences, due to its relative novelty. Examples of such elements include an innovative or novel: (1) product manufacturing technology, such as the dosage form; (2) manufacturing process (e.g., design, scale-up, and/or commercial scale); and/or (3) testing technology.

Budget: Application budgets need to reflect the actual needs of the proposed project and should not exceed the following in total costs (direct and indirect): YR 01: \$1,000,000 YR 02: \$1,000,000 YR 03: \$1,000,000 The scope of the proposed project should determine the project period. The maximum project period is three (3) years.

Brief definitions of some NIH grant mechanisms: [comprehensive list of extramural grant and cooperative agreement activity codes](#)

U01 – NIH Research Project Cooperative Agreement: supports discrete, specified, circumscribed projects to be performed by investigator(s) in an area representing their specific interests and competencies; many types of cooperative agreements, e.g. Clinical Trials Centers; generally no budget upper limit but may be specified.

R01 – NIH Research Project Grant Program: most common NIH program; to support a discrete, specified, circumscribed research project; generally 3-5 years; budget may be specified, but generally <\$500,000 p.a. (direct costs).

R03 – NIH Small Grant Program: limited funding for short period to support e.g. pilot / feasibility study, collection of preliminary data, secondary analysis of existing data, small-contained research projects, development of new research technology, etc.; normally for “new investigators”; not renewable; up to 2 years; budget generally <\$50,000 (direct costs).

UH2/UH3 - Phase Innovation Awards Cooperative Agreement: Exploratory/Developmental Cooperative Agreement Phase I and II. To support the development of new research activities in categorical program areas (Support generally is restricted in level of support and in time.) The UH3 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the UH2 mechanism. Although only UH2 awardees are generally eligible to apply for UH3 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under UH2.

R21 – NIH Exploratory/Developmental Research Grant: encourages new, exploratory and developmental research projects (could be used for pilot or feasibility studies); up to 2 years; budget total generally <\$275,000 (direct costs).

R25 – NIH Education Projects: used in a wide variety of ways to promote an appreciation for and interest in biomedical research, provide additional training in specific areas, and/or to develop ways to disseminate scientific discovery into public health and community applications.

R21/R33 - Phased Innovation: The R33 award is to provide a second phase for the support for innovative exploratory and development research activities initiated under the R21 mechanism. Although only R21 awardees are generally eligible to apply for R33 support, specific program initiatives may establish eligibility criteria under which applications could be accepted from applicants demonstrating progress equivalent to that expected under R33.

G11 Extramural Associate Research Development Award (EARDA) : G11 Extramural Associate Research Development Award (EARDA) To provide funds to institutions eligible to participate in the NIH Extramural Associates Program for establishing or enhancing an office of sponsored research and for other research infrastructure needs.

Complete [Glossary and acronym list of NIH Terms](#)